1887

Abstract

Objectives. Acinetobacter baumannii is a critical nosocomial pathogen. A. baumannii infections have become a grave challenge due to their ability to develop resistance to different antimicrobial agents. The current study aimed to evaluate the potential synergism and bactericidal activity of a combination of colistin and cotrimoxazole against carbapenem-resistant A. baumannii (CRAB) in a Galleria mellonella model.

Methods. Four clinical A. baumannii isolates were biochemically and molecularly identified. Their antimicrobial susceptibility levels were established and the molecular characterization of the carbapenemase-encoding genes was performed. The synergism and bactericidal effect of the colistin/cotrimoxazole combination was assessed using the checkerboard assay and time–kill experiments. An in vivo evaluation of the activity of the combination was performed using the Galleria mellonella model.

Results. A fractional inhibitory concentration index (FICI) of ≤0.5 was found for all strains, indicating that the colistin/cotrimoxazole combination exhibited powerful synergistic activity. The combination displayed both synergistic and bactericidal activity at sub-breakpoint concentrations for all strains. Cotrimoxazole monotherapy showed the least protective activity in the G. mellonella model. The survival rate ranged from 66.7–79.2 % at 24 h and was 29.2–60.4 % at 96 h for the tested isolates. Colistin monotherapy performed better than cotrimoxazole monotherapy; the G. mellonella survival rate ranged from 77.1–97.9 %, at 24 h and from 64.5–72. % at 96 h. The colistin/cotrimoxazole combination improved G. mellonella’s survival rate at 96 h remarkably in comparison to colistin or cotrimoxazole monotherapy.

Conclusions. Finally, the combination of colistin and cotrimoxazole appears to be a promising therapeutic option for the management of CRAB-associated infections. It is essential to assess the clinical application and the dose–response relationships of combinations such as colistin plus cotrimoxazole.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000872
2018-11-13
2020-11-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/68/1/52.html?itemId=/content/journal/jmm/10.1099/jmm.0.000872&mimeType=html&fmt=ahah

References

  1. Alsan M, Klompas M. Acinetobacter baumannii: an emerging and important pathogen. J Clin Outcomes Manag 2010;17:363–369[PubMed]
    [Google Scholar]
  2. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015;36:85–98 [CrossRef][PubMed]
    [Google Scholar]
  3. Chaari A, Mnif B, Bahloul M, Mahjoubi F, Chtara K et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis 2013;17:e1225-8 [CrossRef][PubMed]
    [Google Scholar]
  4. Ulu-Kilic A, Gundogdu A, Cevahir F, Kilic H, Gunes T et al. An outbreak of bloodstream infection due to extensively resistant Acinetobacter baumannii among neonates. Am J Infect Control 2018;46:154–158 [CrossRef][PubMed]
    [Google Scholar]
  5. Marti S, Sánchez-Céspedes J, Blasco MD, Ruiz M, Espinal P et al. Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. Antimicrob Agents Chemother 2008;52:2955–2958 [CrossRef][PubMed]
    [Google Scholar]
  6. Hornsey M, Phee L, Longshaw C, Wareham DW. In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents 2013;41:285–287 [CrossRef][PubMed]
    [Google Scholar]
  7. Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baumannii: from bench to bedside. World J Clin Cases 2014;2:787–814 [CrossRef][PubMed]
    [Google Scholar]
  8. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:5316–5322 [CrossRef][PubMed]
    [Google Scholar]
  9. Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2012;56:4856–4861 [CrossRef][PubMed]
    [Google Scholar]
  10. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8:751–762 [CrossRef][PubMed]
    [Google Scholar]
  11. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC et al. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 2009;53:2605–2609 [CrossRef][PubMed]
    [Google Scholar]
  12. Antunes LC, Imperi F, Minandri F, Visca P. In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2012;56:5961–5970 [CrossRef][PubMed]
    [Google Scholar]
  13. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME et al. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 2006;44:2974–2976 [CrossRef][PubMed]
    [Google Scholar]
  14. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006;27:351–353 [CrossRef][PubMed]
    [Google Scholar]
  15. Chen Y, Zhou Z, Jiang Y, Yu Y. Emergence of NDM-1-producing Acinetobacter baumannii in China. J Antimicrob Chemother 2011;66:1255–1259 [CrossRef][PubMed]
    [Google Scholar]
  16. Lee K, Lim JB, Yum JH, Yong D, Chong Y et al. bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 2002;46:1053–1058 [CrossRef][PubMed]
    [Google Scholar]
  17. Bou G, Cerveró G, Domínguez MA, Quereda C, Martínez-Beltrán J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol 2000;38:3299–3305[PubMed]
    [Google Scholar]
  18. CLSI Performance Standards for Antimicrobial Susceptibility Testing, Twenty-Fourth Informational Supplement. 2014
    [Google Scholar]
  19. Milne KE, Gould IM. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J Antimicrob Chemother 2010;65:82–90 [CrossRef][PubMed]
    [Google Scholar]
  20. Markantonis SL, Markou N, Fousteri M, Sakellaridis N, Karatzas S et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009;53:4907–4910 [CrossRef][PubMed]
    [Google Scholar]
  21. Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 2009;8:18 [CrossRef][PubMed]
    [Google Scholar]
  22. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 2010;16:35–40 [CrossRef][PubMed]
    [Google Scholar]
  23. Al-Agamy MH, Khalaf NG, Tawfick MM, Shibl AM, El Kholy A. Molecular characterization of carbapenem-insensitive Acinetobacter baumannii in Egypt. Int J Infect Dis 2014;22:49–54 [CrossRef][PubMed]
    [Google Scholar]
  24. Ghaith DM, Zafer MM, Al-Agamy MH, Alyamani EJ, Booq RY et al. The emergence of a novel sequence type of MDR Acinetobacter baumannii from the intensive care unit of an Egyptian tertiary care hospital. Ann Clin Microbiol Antimicrob 2017;16:34 [CrossRef][PubMed]
    [Google Scholar]
  25. Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A et al. Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. Biomed Res Int 2014;2014:1–11 [CrossRef]
    [Google Scholar]
  26. Uwingabiye J, Lemnouer A, Roca I, Alouane T, Frikh M et al. Clonal diversity and detection of carbapenem resistance encoding genes among multidrug-resistant Acinetobacter baumannii isolates recovered from patients and environment in two intensive care units in a Moroccan hospital. Antimicrob Resist Infect Control 2017;6:99 [CrossRef][PubMed]
    [Google Scholar]
  27. Zowawi HM, Sartor AL, Sidjabat HE, Balkhy HH, Walsh TR et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolates in the Gulf Cooperation Council States: dominance of OXA-23-type producers. J Clin Microbiol 2015;53:896–903 [CrossRef][PubMed]
    [Google Scholar]
  28. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012;67:1607–1615 [CrossRef][PubMed]
    [Google Scholar]
  29. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 2011;66:2070–2074 [CrossRef][PubMed]
    [Google Scholar]
  30. Dobrewski R, Savov E, Bernards AT, van den Barselaar M, Nordmann P et al. Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital. Clin Microbiol Infect 2006;12:1135–1137 [CrossRef][PubMed]
    [Google Scholar]
  31. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012;25:450–470 [CrossRef][PubMed]
    [Google Scholar]
  32. Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011;66:1047–1051 [CrossRef][PubMed]
    [Google Scholar]
  33. Nepka M, Perivolioti E, Kraniotaki E, Politi L, Tsakris A et al. In vitro bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 2016;60:6903–6906 [CrossRef][PubMed]
    [Google Scholar]
  34. Falagas ME, Vardakas KZ, Roussos NS. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: a review of current microbiological and clinical evidence. Int J Antimicrob Agents 2015;46:231–241 [CrossRef][PubMed]
    [Google Scholar]
  35. Rubin BK, Tamaoki J. Antibiotics as Anti-Inflammatory and Immunomodulatory Agents Basel; Boston: Birkhäuser; 2005;273
    [Google Scholar]
  36. Krezdorn J, Adams S, Coote PJ. A Galleria mellonella infection model reveals double and triple antibiotic combination therapies with enhanced efficacy versus a multidrug-resistant strain of Pseudomonas aeruginosa. J Med Microbiol 2014;63:945–955 [CrossRef][PubMed]
    [Google Scholar]
  37. Betts JW, Phee LM, Woodford N, Wareham DW. Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 2014;33:1565–1572 [CrossRef][PubMed]
    [Google Scholar]
  38. Lionakis MS. Drosophila and Galleria insect model hosts: new tools for the study of fungal virulence, pharmacology and immunology. Virulence 2011;2:521–527 [CrossRef][PubMed]
    [Google Scholar]
  39. Hamouche E, Sarkis DK. Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009. Pathol Biol 2012;60:e15-20 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000872
Loading
/content/journal/jmm/10.1099/jmm.0.000872
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error